David Ricks, Eli Lilly CEO (AP Photo/Carolyn Kaster)
June 29, 2023 07:34 AM EDTUpdated 11:40 AM
Deals
Pharma
Cell/Gene Tx

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

Kyle LaHucik

Senior Reporter

Eli Lil­ly will buy its di­a­betes cell ther­a­py part­ner Sig­ilon Ther­a­peu­tics, which came out of Flag­ship Pi­o­neer­ing, about five years af­ter the two com­pa­nies first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times